Xcell™
Eng-HEK293
Cell Line

High Performance Engineered Xcell™ HEK293 Cell Line for Transient rAAV Production.
Introducing our proprietary  Xcell™ Eng-HEK293 Cell Line for reliable and efficient rAAV pre-clinical and commercial production.
This high performance Engineered HEK293 cell line for transient rAAV production is now available to license for use in your laboratory or production facility!

Xcell™ Eng-HEK293 is a HEK293 suspension host cell line that has been precision-engineered for high rAAV productivity and production, while maintaining phenotypic and genomic stability. With a comprehensive genetic makeup package, Eng-HEK293 it's an ideal choice for in-house transient transfection processes and scalable production. By streamlining manufacturing processes, NewBiologix facilitates faster and more cost-effective delivery of life-changing gene therapies to patients worldwide.

Key Advantages of Xcell™ Eng-HEK293

High rAAV Production
Meticulously selected cell clone for optimal rAAV production
High rAAV Production
Completely characterized and traceable cell line for reliable results.
Genomic Stability
Enhanced stability with chromosome number remaining stable over 60 generations.
Robust Growth
Optimal doubling time and high-density culture performance with fast recovery.
High-Density Growth
Suspension growth to high cell density in defined media.
Long-Term Stability
Consistent growth characteristics maintained for 60 generations.
Efficient Transfection
Improved efficiencies using chemical transfection and electroporation methods.
Superior Production
Higher rAAV titers and greater reliability compared to polyclonal HEK293.
Scalable Process
Enables reliable and scalable rAAV production for various applications.

Superior rAAV Titers for Multiple Serotypes

Now Available to Take to Your Laboratory!

Our technology provides a seamless extension of your capabilities and adapts to your program’s evolving needs
Contact us to discuss your AAV development and manufacturing needs and to gain access to Xcell™ Eng-HEK293 to unlock the full potential of your gene therapy research.